Drug Information
| General Information | ||||||
|---|---|---|---|---|---|---|
| Drug ID |
DR00613
|
|||||
| Drug Name |
Dipyridamole
|
|||||
| Synonyms |
2,6-Bis(diethanolamine)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine; 2,6-Bis(diethanolamino)-4,8-dipiperidinopyrimido(5,4-d)pyrimidine; 2,6-Bis(diethanolamino)-4,8-dipiperidinopyrimido[5,4-d]pyrimidine; Agilease; Anginal; Antistenocardin; Apo-Dipyridamole; Apo-Dipyridamole Fc; Apo-Dipyridamole Sc; Apotex Brand of Dipyridamole; Apricor; Ashbourne Brand of Dipyridamole; Belmac Brand of Dipyridamole; Berlin Chemie Brand of Dipyridamole; Berlin-Chemie Brand of Dipyridamole; Boehringer Ingelheim Brand of Dipyridamole; Cardioflux; Cardoxil; Cardoxin; Cerebrovase; Chilcolan; Cleridium; Cleridium 150; Coribon; Coridil; Coronarine; Corosan; Coroxin; Curantil; Curantyl; D 9766; Dipiridamol; Dipiridamol [INN-Spanish]; Dipyramidole; Dipyridamine; Dipyridamol; Dipyridamole (JP15/USP/INN); Dipyridamole [USAN:INN:BAN:JAN]; Dipyridamolum; Dipyridamolum [INN-Latin]; Dipyridan; Dipyudamine; Dypyridamol; Gulliostin; IPRAD Brand of Dipyridamole; Iv Persantine; Justpertin; Kurantil; Miosen; Natyl; Novo-Dipiradol; Novopharm Brand of Dipyridamole; Peridamol; Permiltin; Permole, Persantine, Dipyridan, Dipyridamole; Persantin; Persantine; Persantine (TN); Piroan; Prandiol; Prandiol 75; Protangix; RA-8; Stenocardil; Stenocardiol; Stimolcardio; Usaf Ge-12
|
|||||
| Drug Type |
Small molecular drug
|
|||||
| Indication | High blood pressure [ICD11: BA00] | Approved | [1] | |||
| Therapeutic Class |
Vasodilator Agents
|
|||||
| Structure |
|
 |
||||
| 3D MOL | 2D MOL | |||||
| Formula |
C24H40N8O4
|
|||||
| Canonical SMILES |
C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO
|
|||||
| InChI |
InChI=1S/C24H40N8O4/c33-15-11-31(12-16-34)23-26-20-19(21(27-23)29-7-3-1-4-8-29)25-24(32(13-17-35)14-18-36)28-22(20)30-9-5-2-6-10-30/h33-36H,1-18H2
|
|||||
| InChIKey |
IZEKFCXSFNUWAM-UHFFFAOYSA-N
|
|||||
| CAS Number |
CAS 58-32-2
|
|||||
| Pharmaceutical Properties | Molecular Weight | 504.6 | Topological Polar Surface Area | 145 | ||
| Heavy Atom Count | 36 | Rotatable Bond Count | 12 | |||
| Hydrogen Bond Donor Count | 4 | Hydrogen Bond Acceptor Count | 12 | |||
| XLogP |
0.7
|
|||||
| PubChem CID | ||||||
| PubChem SID |
10321246
, 10528232
, 10589644
, 11111116
, 11111117
, 11113358
, 11335871
, 11361110
, 11363898
, 11366460
, 11369022
, 11371244
, 11374262
, 11377184
, 11410079
, 11462082
, 11466170
, 11467290
, 11484739
, 11485919
, 11488788
, 11490218
, 11492337
, 11494818
, 12054904
, 14811101
, 17405027
, 22391481
, 24277705
, 26611713
, 26680947
, 26747068
, 26747069
, 26751580
, 26751581
, 26758633
, 29222251
, 46487910
, 46506292
, 47291146
, 47291147
, 480294
, 489152
, 5052822
, 612448
, 7847368
, 7979106
, 8149314
, 8151978
, 855977
|
|||||
| ChEBI ID |
ChEBI:4653
|
|||||
| TTD Drug ID | ||||||
| DT(s) Transporting This Drug | BCRP | Transporter Info | Breast cancer resistance protein | Substrate | [2] | |
| P-GP | Transporter Info | P-glycoprotein 1 | Substrate | [3] | ||
| References | ||||||
| 1 | Dipyridamole was approved by FDA. The official website of the U.S. Food and Drug Administration. (2019) | |||||
| 2 | ABCG2: a perspective. Adv Drug Deliv Rev. 2009 Jan 31;61(1):3-13. | |||||
| 3 | Improving the prediction of the brain disposition for orally administered drugs using BDDCS. Adv Drug Deliv Rev. 2012 Jan;64(1):95-109. | |||||
If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.